Are glycans related to the tissue targeting performance of Adeno-associated virus (AAV)?

In gene therapy using Adeno-associated virus (AAV), it has been suggested that there are some differences in AAV capsids in terms of tissue targeting ability, and it has been told that glycans may be involved in he AAV’s tissue targeting ability. Such arguments have been around for quite some time.
For example, the following papers are references.
https://www.nature.com/articles/gt201316
https://www.jbc.org/article/S0021-9258(20)51734-1/fulltext
https://www.jbc.org/article/S0021-9258(20)48853-2/fulltext
https://jvi.asm.org/content/80/18/9093

Specifically, it has been reported that AAV-1 and AAV-6 bind to Sialic acid, AAV-2 binds to Heparan sulfate, and AAV-9 binds to Galatose.
But, is it true?
To this blog admin., it is a kind of unbelievable thing that capsid proteins have lectin-like functions?